Technology

Technology Overview

Our approach, based on Nano-technology, has allowed us to develop a powerful and highly specific pharmacological platform designed to treat and cure Autoimmune diseases. In this type of disorder, one’s own immune system mistakenly attacks one’s own cells or tissue. Depending on the specific tissue attacked, a different disease is developed: Celiac disease, Multiple Sclerosis, Type 1 Diabetes, Rheumatoid Arthritis, and Psoriasis, to mention only a few of more than 100 recognized Autoimmune diseases.

To re-establish immune tolerance against self-tissues, AHEAD THERAPEUTICS S.L. has developed a technology based on bio-mimicking Efferocytosis, a crucial and well-known physiological process involved in ‘Antigen-Specific Immune Tolerance Induction’, whereby apoptotic cells are removed from the body by being recognized, recruited, and engulfed by immature dendritic cells (DCs).

Our technological platform contains a wide range of Liposomes based on Phosphatidylserine and other endogenous mammal compounds. These Liposomes are of certain particle size and are accurately produced to encapsulate a specific Autoantigen, depending on the illness to be treated.

By administering our Liposomes with Phosphatidylserine in the outer membrane, Apoptosis in cells is simulated to trigger the Efferocytosis mechanism and generate not only Specific Tolerance against the encapsulated Autoantigen but also to induce immunological memory.

Furthermore, as our approach is not HLA dependent, personalized treatment is not required, adding a major economical advantage to the platform.

Publications

Significant references related to Ahead Therapeutics SL.